Gubra A/S (GUBRA.CO)
- Previous Close
299.00 - Open
298.00 - Bid 300.00 x --
- Ask 302.00 x --
- Day's Range
294.00 - 303.00 - 52 Week Range
83.45 - 359.00 - Volume
19,888 - Avg. Volume
64,600 - Market Cap (intraday)
4.92B - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-2.90 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Gubra A/S operates as a biotech company with two primary areas of business: pre-clinical contract research (CRO) services and proprietary early target and drug discovery programs in Denmark and internationally. The company operates through CRO, Discovery & Partnerships, and Gubra Green segments. It offers pre-clinical contract research and development services within metabolic and fibrotic diseases for the pharmaceutical and biotechnology industry, as well as provides services in vivo pharmacology, assays and molecular pharmacology, bioinformatics, bioanalysis, next gen sequencing, and 2D and 3D imaging. The company has a partnership and collaboration with Boehringer Ingelheim to discover novel peptides for the treatment of obesity. Gubra A/S was incorporated in 2008 and is based in Horsholm, Denmark.
www.gubra.dkRecent News: GUBRA.CO
Performance Overview: GUBRA.CO
Trailing total returns as of 5/17/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: GUBRA.CO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: GUBRA.CO
Valuation Measures
Market Cap
4.92B
Enterprise Value
4.94B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
22.35
Price/Book (mrq)
10.26
Enterprise Value/Revenue
24.09
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-21.72%
Return on Assets (ttm)
-6.71%
Return on Equity (ttm)
-15.15%
Revenue (ttm)
205M
Net Income Avi to Common (ttm)
-44.52M
Diluted EPS (ttm)
-2.90
Balance Sheet and Cash Flow
Total Cash (mrq)
457.39M
Total Debt/Equity (mrq)
14.89%
Levered Free Cash Flow (ttm)
-1.21M
Research Analysis: GUBRA.CO
Company Insights: GUBRA.CO
GUBRA.CO does not have Company Insights